{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:11:44Z","timestamp":1781525504170,"version":"3.54.1"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Multiple myeloma therapy has made remarkable progress with the advent of new drugs. We explored the treatment pattern and outcomes in Japanese patients with multiple myeloma using the Medical Data Vision database. Patients were categorized as per the initial diagnosis period (2003\u20132015 and 2016\u20132020), considering the adoption of these new agents and then based on stem cell transplantation. Overall, 6438 patient data were extracted as eligible for data analysis, and the median age at the index diagnosis date was 72.0 years. Bortezomib\/dexamethasone was the most common regimen for induction therapy in patients requiring stem cell transplantation from 2003\u20132015, and the use of bortezomib\/lenalidomide\/dexamethasone increased from 2016\u20132020. Lenalidomide\/dexamethasone was the most commonly used post-transplant therapy. In the non-stem cell transplantation group, bortezomib\/dexamethasone was mainly used for both periods, while lenalidomide\/dexamethasone was primarily used from 2016\u20132020. There was a trend toward shorter first-line treatment duration and a shift to additional treatment patterns with new drugs at the following lines. The time to inpatient death period suggested an improvement between the two periods. Thus, this study revealed that recent diversification of treatment options is preferred and contributes to improved outcomes in the clinical practice of multiple myeloma in Japan.<\/jats:p>","DOI":"10.1371\/journal.pone.0283931","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T17:39:29Z","timestamp":1680802769000},"page":"e0283931","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database"],"prefix":"10.1371","volume":"18","author":[{"given":"Hiroshi","family":"Handa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-0752","authenticated-orcid":true,"given":"Shuji","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7361-114X","authenticated-orcid":true,"given":"Asuka","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"pone.0283931.ref001","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"MS Raab","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"pone.0283931.ref002","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/13696998.2019.1686870","article-title":"Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims database","volume":"23","author":"S Uno","year":"2020","journal-title":"J Med Econ"},{"issue":"7","key":"pone.0283931.ref003","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.23731","article-title":"Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study","volume":"89","author":"K Kim","year":"2014","journal-title":"Am J Hematol"},{"key":"pone.0283931.ref004","unstructured":"National Cancer Registry (Ministry of Health, Labour and Welfare), tabulated by Cancer Information Service, National Cancer Center, Japan. (2016\u20132018), 2021. Accessed July 19, 2022. https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html"},{"issue":"7","key":"pone.0283931.ref005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00277-019-03702-1","article-title":"Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma","volume":"98","author":"S Ozaki","year":"2019","journal-title":"Ann Hematol"},{"issue":"2","key":"pone.0283931.ref006","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jjco\/hys215","article-title":"Current therapeutic strategy for multiple myeloma","volume":"43","author":"K. Suzuki","year":"2013","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"pone.0283931.ref007","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12185-019-02636-8","article-title":"JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM)","volume":"109","author":"S Iida","year":"2019","journal-title":"Int J Hematol"},{"issue":"2","key":"pone.0283931.ref008","first-page":"45","article-title":"Treatment Patterns in Newly Diagnosed Multiple Myeloma Patients in Japan Using A Large-scale Claims Database: Retrospective Cohort Study","volume":"25","author":"J Guan","year":"2020","journal-title":"Japanese J of Pharm Epi"},{"issue":"4","key":"pone.0283931.ref009","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3747\/co.21.1798","article-title":"Bortezomib in multiple myeloma: systematic review and clinical considerations","volume":"21","author":"TC Kouroukis","year":"2014","journal-title":"Curr Oncol"},{"issue":"5","key":"pone.0283931.ref010","doi-asserted-by":"crossref","first-page":"e64354","DOI":"10.1371\/journal.pone.0064354","article-title":"Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"B Yang","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"pone.0283931.ref011","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"PG Richardson","year":"2014","journal-title":"Blood"},{"issue":"8","key":"pone.0283931.ref012","doi-asserted-by":"crossref","first-page":"11081","DOI":"10.1007\/s13277-016-4963-8","article-title":"Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials","volume":"37","author":"M Gao","year":"2016","journal-title":"Tumour Biol"},{"key":"pone.0283931.ref013","unstructured":"JSH practical guidelines for hematological malignancies, 2013: III. Myeloma-1. Multiple myeloma (MM). Accessed July 19, 2022. http:\/\/www.jsco-cpg.jp\/item\/12\/index.html."},{"key":"pone.0283931.ref014","unstructured":"JSH practical guidelines for hematological malignancies, 2020: III. Myeloma-1. Multiple myeloma (MM). Accessed July 19, 2022. http:\/\/www.jshem.or.jp\/gui-hemali\/3_1.html."},{"issue":"22","key":"pone.0283931.ref015","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1182\/blood.V128.22.5950.5950","article-title":"Patient Characteristics, Treatment Patterns and Outcomes Among Relapsed\/Refractory Multiple Myeloma (RRMM) Patients in Japan","volume":"128","author":"G Jun","year":"2016","journal-title":"Blood"},{"issue":"12","key":"pone.0283931.ref016","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1111\/cas.15163","article-title":"Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine","volume":"112","author":"Y Shimazu","year":"2021","journal-title":"Cancer Sci"},{"key":"pone.0283931.ref017","unstructured":"Okayama Y. Very elderly patients with myeloma: a multicenter retrospective analysis from Kansai Myeloma forum. Presented at 83rd Annual Meeting of the Japanese Society of Hematology (JSH2021) [OS-1-9D-1]. 2021."},{"issue":"1","key":"pone.0283931.ref018","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12185-019-02764-1","article-title":"Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis","volume":"111","author":"K Suzuki","year":"2020","journal-title":"Int J Hematol"},{"issue":"8","key":"pone.0283931.ref019","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1007\/s10147-019-01436-8","article-title":"Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12)","volume":"24","author":"K Sunami","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"pone.0283931.ref020","unstructured":"Sunami K, Nagafuji K, Kamimura T, Miyamoto T, Matsumoto M, Ogawa R, et al. Phase 2 study of autologous stem cell transplantation for untreated multiple myeloma (JSCT-MM14). The Annual Meeting of the Japanese Society of Hematology (Web), abstract 857, 82nd, 2020. Accessed Aug 05, 2022. http:\/\/www.jshem.or.jp\/82\/en\/."},{"issue":"19","key":"pone.0283931.ref021","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"M Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0283931.ref022","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"AK Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"pone.0283931.ref023","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"MA Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0283931.ref024","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjh.14787","article-title":"Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth","volume":"178","author":"MA Dimopoulos","year":"2017","journal-title":"Br J Haematol"},{"issue":"7","key":"pone.0283931.ref025","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"S Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0283931.ref026","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3324\/haematol.2017.170118","article-title":"Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in TOURMALINE-MM1","volume":"102","author":"MV Mateos","year":"2017","journal-title":"Haematologica"},{"issue":"17","key":"pone.0283931.ref027","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"P Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"20","key":"pone.0283931.ref028","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","article-title":"Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR\/IFM 2005\u201304 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"L Garderet","year":"2012","journal-title":"J Clin Oncol"},{"key":"pone.0283931.ref029","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.critrevonc.2017.03.018","article-title":"Triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma: A meta-analysis of phase III randomized controlled trials","volume":"113","author":"Z Sun","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10245","key":"pone.0283931.ref030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"M Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"pone.0283931.ref031","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"A Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0283931.ref032","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1038\/bcj.2015.79","article-title":"Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma","volume":"5","author":"S Ozaki","year":"2015","journal-title":"Blood Cancer J"},{"issue":"1","key":"pone.0283931.ref033","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cam4.2656","article-title":"Connect MM Registry as a national reference for United States multiple myeloma patients","volume":"9","author":"S Ailawadhi","year":"2020","journal-title":"Cancer Med"},{"issue":"5","key":"pone.0283931.ref034","doi-asserted-by":"crossref","first-page":"e66116","DOI":"10.1371\/journal.pone.0066116","article-title":"Claims-based definition of death in Japanese claims database: validity and implications","volume":"8","author":"N Ooba","year":"2013","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0283931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T17:39:53Z","timestamp":1680802793000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0283931"}},"subtitle":[],"editor":[{"given":"Hideki","family":"Maeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0283931","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}